CD274 and laryngotracheoesophageal cleft: In the future, research on the relationship between the expression level of PD-L1 and the efficacy of immunotherapy, as well as the detailed molecular mechanisms by which COPD affects the TIME and ICI efficacy, would provide a novel basis for ICI treatment in LC patients with COPD.